NCR3 and neoplasm: In contrast to NKp30-Ig and in agreement with the results presented above (figure 2), NKp46D2-Ig treatment had only a marginal effect (figure 3b and 4); 66.6% of the mice treated with NKp46D2-Ig showed progressive tumor growth, while 22.2% and 11.1% were partially cured or effectively treated, respectively.